Pasithea Therapeutics Ownership 2024 | Who Owns Pasithea Therapeutics Now?

Institutional Ownership

0.99%

Institutional Holders

8.00

Pasithea Therapeutics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
JPMORGAN CHASE & CO	-	-	-	-3,000	-100.00%	-	Mar 31, 2024
WELLS FARGO & COMPANY/MN	-	-	-	-127	-100.00%	-	Mar 31, 2024
NORTHERN TRUST CORP	-	-	-	-47,074	-100.00%	-	Mar 31, 2024
ROYAL BANK OF CANADA	-	-	-	-5,000	-100.00%	-	Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC	-	-	-	-32,500	-100.00%	-	Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-125,123	-100.00%	-	Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-12,396	-100.00%	-	Mar 31, 2024
JANE STREET GROUP, LLC	-	-	-	-23,588	-100.00%	-	Mar 31, 2024

Pasithea Therapeutics's largest institutional shareholder is JPMORGAN CHASE & CO, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
JPMORGAN CHASE & CO	-	-	-	-3,000	-100.00%	-	Mar 31, 2024
WELLS FARGO & COMPANY/MN	-	-	-	-127	-100.00%	-	Mar 31, 2024
NORTHERN TRUST CORP	-	-	-	-47,074	-100.00%	-	Mar 31, 2024
ROYAL BANK OF CANADA	-	-	-	-5,000	-100.00%	-	Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC	-	-	-	-32,500	-100.00%	-	Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-125,123	-100.00%	-	Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-12,396	-100.00%	-	Mar 31, 2024
JANE STREET GROUP, LLC	-	-	-	-23,588	-100.00%	-	Mar 31, 2024

The largest Pasithea Therapeutics shareholder by % of total assets is JPMORGAN CHASE & CO. The company owns 0.00 shares of Pasithea Therapeutics (KTTA), representing 0.00% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
WELLS FARGO & COMPANY/MN	-	-	-	-127	-100.00%	-	Mar 31, 2024
JPMORGAN CHASE & CO	-	-	-	-3,000	-100.00%	-	Mar 31, 2024
ROYAL BANK OF CANADA	-	-	-	-5,000	-100.00%	-	Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-12,396	-100.00%	-	Mar 31, 2024
JANE STREET GROUP, LLC	-	-	-	-23,588	-100.00%	-	Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC	-	-	-	-32,500	-100.00%	-	Mar 31, 2024
NORTHERN TRUST CORP	-	-	-	-47,074	-100.00%	-	Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-125,123	-100.00%	-	Mar 31, 2024

As of Mar 31 2024, Pasithea Therapeutics's largest institutional buyer is WELLS FARGO & COMPANY/MN. The company purchased -0.13K stocks of KTTA, valued at -.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-125,123	-100.00%	-	Mar 31, 2024
NORTHERN TRUST CORP	-	-	-	-47,074	-100.00%	-	Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC	-	-	-	-32,500	-100.00%	-	Mar 31, 2024
JANE STREET GROUP, LLC	-	-	-	-23,588	-100.00%	-	Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-12,396	-100.00%	-	Mar 31, 2024
ROYAL BANK OF CANADA	-	-	-	-5,000	-100.00%	-	Mar 31, 2024
JPMORGAN CHASE & CO	-	-	-	-3,000	-100.00%	-	Mar 31, 2024
WELLS FARGO & COMPANY/MN	-	-	-	-127	-100.00%	-	Mar 31, 2024

As of Mar 31 2024, Pasithea Therapeutics's biggest institutional seller is GEODE CAPITAL MANAGEMENT, LLC. The company sold -0.13M shares of KTTA, valued at -.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-125,123	-100.00%	-	Mar 31, 2024
NORTHERN TRUST CORP	-	-	-	-47,074	-100.00%	-	Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC	-	-	-	-32,500	-100.00%	-	Mar 31, 2024
JANE STREET GROUP, LLC	-	-	-	-23,588	-100.00%	-	Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-12,396	-100.00%	-	Mar 31, 2024
ROYAL BANK OF CANADA	-	-	-	-5,000	-100.00%	-	Mar 31, 2024
JPMORGAN CHASE & CO	-	-	-	-3,000	-100.00%	-	Mar 31, 2024
WELLS FARGO & COMPANY/MN	-	-	-	-127	-100.00%	-	Mar 31, 2024

Pasithea Therapeutics's largest sold out institutional shareholder by shares sold is GEODE CAPITAL MANAGEMENT, LLC, sold -0.13M shares, valued at -, as of undefined.

Pasithea Therapeutics Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
FIDELITY CONCORD STREET TRUST	0.00%	117,393	-	-	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	138,145	-	-	Mar 31, 2024
EQ ADVISORS TRUST	0.00%	967	-	-	Mar 31, 2024
iSHARES TRUST	0.00%	8,995	-	-	Mar 31, 2024

Pasithea Therapeutics's largest mutual fund holder by % of total assets is "FIDELITY CONCORD STREET TRUST", owning 117.39K shares, compromising 0.00% of its total assets.

Pasithea Therapeutics Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
31 Dec, 23	8	-33.33%
30 Sep, 23	12	-
30 Jun, 23	12	-
31 Mar, 23	12	9.09%
31 Dec, 22	11	37.50%
30 Sep, 22	8	-
30 Jun, 22	8	14.29%
31 Mar, 22	7	16.67%
31 Dec, 21	6	50.00%
30 Sep, 21	4	-

As of 31 Dec 23, 8 institutions are holding Pasithea Therapeutics's shares, representing a decrease of -33.33% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
31 Dec, 23	248,808	-2.59%
30 Sep, 23	255,417	-32.44%
30 Jun, 23	378,085	-1.83%
31 Mar, 23	385,124	-39.00%
31 Dec, 22	631,393	-22.91%
30 Sep, 22	818,998	27.19%
30 Jun, 22	643,939	-14.98%
31 Mar, 22	757,381	23.29%
31 Dec, 21	614,318	47.83%
30 Sep, 21	415,564	-

Pasithea Therapeutics (KTTA) has 248.81K shares outstanding as of 31 Dec 23, down -2.59% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
31 Dec, 23	0.99%	103.48%
30 Sep, 23	0.98%	46.49%
30 Jun, 23	1.45%	66.46%
31 Mar, 23	1.48%	23.62%
31 Dec, 22	2.50%	26.27%
30 Sep, 22	3.08%	40.89%
30 Jun, 22	2.75%	25.35%
31 Mar, 22	3.29%	46.18%
31 Dec, 21	2.67%	81.85%
30 Sep, 21	1.81%	-

As of 31 Dec 23, Pasithea Therapeutics is held by 0.99% institutional shareholders, representing a 103.48% growth compared to 30 Sep 23.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
31 Dec, 23	3	-57.14%
30 Sep, 23	7	40.00%
30 Jun, 23	5	25.00%
31 Mar, 23	4	-50.00%
31 Dec, 22	8	100.00%
30 Sep, 22	4	-33.33%
30 Jun, 22	6	20.00%
31 Mar, 22	5	-16.67%
31 Dec, 21	6	50.00%
30 Sep, 21	4	-

3 institutional shareholders have increased their position in KTTA stock as of 31 Dec 23 compared to 7 in the previous quarter (a -57.14% decrease).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
31 Dec, 23	2	-33.33%
30 Sep, 23	3	-
30 Jun, 23	3	-
31 Mar, 23	3	50.00%
31 Dec, 22	2	100.00%
30 Sep, 22	1	-
30 Jun, 22	1	-
31 Mar, 22	-	-
31 Dec, 21	-	-
30 Sep, 21	-	-

2 institutional shareholders have reduced their position in KTTA stock as of 31 Dec 23 compared to 3 in the previous quarter (a -33.33% decrease).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
31 Dec, 23	8	-33.33%	248,808	-2.59%	0.99%	103.48%	3	-57.14%	2	-33.33%
30 Sep, 23	12	-	255,417	-32.44%	0.98%	46.49%	7	40.00%	3	-
30 Jun, 23	12	-	378,085	-1.83%	1.45%	66.46%	5	25.00%	3	-
31 Mar, 23	12	9.09%	385,124	-39.00%	1.48%	23.62%	4	-50.00%	3	50.00%
31 Dec, 22	11	37.50%	631,393	-22.91%	2.50%	26.27%	8	100.00%	2	100.00%
30 Sep, 22	8	-	818,998	27.19%	3.08%	40.89%	4	-33.33%	1	-
30 Jun, 22	8	14.29%	643,939	-14.98%	2.75%	25.35%	6	20.00%	1	-
31 Mar, 22	7	16.67%	757,381	23.29%	3.29%	46.18%	5	-16.67%	-	-
31 Dec, 21	6	50.00%	614,318	47.83%	2.67%	81.85%	6	50.00%	-	-
30 Sep, 21	4	-	415,564	-	1.81%	-	4	-	-	-

Pasithea Therapeutics Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jun 14, 2024	Novak Alfred J	director	-	A-Award	Buy	2,750	$5.62	$15.46K	3,500
Jun 14, 2024	Novak Alfred J	director	-	A-Award	Buy	750	$5.61	$4.21K	750
Apr 05, 2024	Marques Tiago	director, officer	Chief Executive Officer	A-Award	Buy	15,000	$8.13	$121.95K	15,000
Apr 05, 2024	Marques Tiago	director, officer	Chief Executive Officer	A-Award	Buy	11,669	$8.13	$94.87K	11,669
Apr 05, 2024	Dumesnil Simon	director	-	A-Award	Buy	7,500	$8.13	$60.98K	7,500
Apr 05, 2024	Schneiderman Daniel H	officer	Chief Financial Officer	A-Award	Buy	10,000	$8.13	$81.30K	10,000
Apr 05, 2024	Schneiderman Daniel H	officer	Chief Financial Officer	A-Award	Buy	5,927	$8.13	$48.19K	5,927
Apr 05, 2024	Leahy Emer	director	-	A-Award	Buy	7,500	$8.13	$60.98K	7,500
Apr 05, 2024	Novak Alfred J	director	-	A-Award	Buy	5,000	$8.13	$40.65K	5,000
Apr 05, 2024	Currie Graeme Martin	officer	Chief Development Officer	A-Award	Buy	5,938	$8.13	$48.28K	5,938
Apr 05, 2024	STEINMAN LAWRENCE	director	-	A-Award	Buy	7,500	$8.13	$60.98K	7,500
Mar 01, 2024	STEINMAN LAWRENCE	director	-	A-Award	Buy	7,500	$8.34	$62.55K	7,500
Mar 01, 2024	Schneiderman Daniel H	officer	Chief Financial Officer	A-Award	Buy	10,000	$8.34	$83.40K	10,000
Mar 01, 2024	Schneiderman Daniel H	officer	Chief Financial Officer	A-Award	Buy	5,927	$8.34	$49.43K	5,927
Mar 01, 2024	Novak Alfred J	director	-	A-Award	Buy	5,000	$8.34	$41.70K	5,000
Mar 01, 2024	Marques Tiago	director, officer	Chief Executive Officer	A-Award	Buy	15,000	$8.34	$125.10K	15,000
Mar 01, 2024	Marques Tiago	director, officer	Chief Executive Officer	A-Award	Buy	11,669	$8.34	$97.32K	11,669
Mar 01, 2024	Leahy Emer	director	-	A-Award	Buy	7,500	$8.34	$62.55K	7,500
Mar 01, 2024	Dumesnil Simon	director	-	A-Award	Buy	7,500	$8.34	$62.55K	7,500
Mar 01, 2024	Currie Graeme Martin	officer	Chief Development Officer	A-Award	Buy	5,938	$8.34	$49.52K	5,938

Pasithea Therapeutics Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q2 2024	2	-	-
Q1 2024	18	-	-
Q2 2023	1	1	100.00%
Q4 2022	16	2	800.00%
Q3 2022	13	-	-
Q2 2022	8	-	-
Q4 2021	2	-	-
Q3 2021	2	3	66.67%

2 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Pasithea Therapeutics's insiders, as of Q2 2024.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q2 2024	-	-	-
Q1 2024	-	-	-
Q2 2023	1	-	-
Q4 2022	1	-	-
Q3 2022	13	-	-
Q2 2022	-	-	-
Q4 2021	-	-	-
Q3 2021	-	-	-

As of Q2 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Pasithea Therapeutics's stocks.

Pasithea Therapeutics Peer Ownership

Ticker	Company
BWV	Onconetix, Inc.
ABVC	ABVC BioPharma, Inc.
KPRX	Kiora Pharmaceuticals, Inc.
PXMD	PaxMedica, Inc. Common Stock
REVB	Revelation Biosciences, Inc.
QNRX	Quoin Pharmaceuticals, Ltd.
HILS	Tharimmune, Inc.
KRON	Kronos Bio, Inc.
VRAX	Virax Biolabs Group Limited
MNOV	MediciNova, Inc.
RNXT	RenovoRx, Inc.
INDP	Indaptus Therapeutics, Inc.
KZR	Kezar Life Sciences, Inc.
FBRX	Forte Biosciences, Inc.
ELYM	Eliem Therapeutics, Inc.

KTTA Ownership FAQ

Who Owns Pasithea Therapeutics?

Pasithea Therapeutics is owned by institutional shareholders (0.99%), insiders (0.00%), and public (99.01%). The largest institutional shareholder of Pasithea Therapeutics is JPMORGAN CHASE & CO (0% of total shares) and the top mutual fund owner is FIDELITY CONCORD STREET TRUST (0.00% of total shares).

Who are the major institutional shareholders of Pasithea Therapeutics?

Pasithea Therapeutics's major institutional shareholders are JPMORGAN CHASE & CO, WELLS FARGO & COMPANY/MN, NORTHERN TRUST CORP, ROYAL BANK OF CANADA, and RENAISSANCE TECHNOLOGIES LLC. The top five shareholders own together 0% of the company's share outstanding.

How many Pasithea Therapeutics shareholders are there?

As of Dec 2023, there are 8 institutional shareholders of Pasithea Therapeutics.

What percentage of Pasithea Therapeutics is owned by JPMORGAN CHASE & CO?

JPMORGAN CHASE & CO owns 0 shares of Pasithea Therapeutics, representing 0% of the company's total shares outstanding, valued at $0 (as of Mar 2024).

What percentage of Pasithea Therapeutics is owned by WELLS FARGO & COMPANY/MN?

As of Mar 2024, WELLS FARGO & COMPANY/MN holds 0 shares of Pasithea Therapeutics (KTTA), compromising 0% of the company, valued at $0.

What percentage of Pasithea Therapeutics is owned by NORTHERN TRUST CORP?

NORTHERN TRUST CORP is the third largest holder of Pasithea Therapeutics. The company owns 0 of the company's shares outstanding (worth $0).